| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Andreas Hochhaus | Q37829812 |
| P304 | page(s) | x274-9 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors | |
| P478 | volume | 17 Suppl 10 |
| Q35991845 | A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line. |
| Q64064218 | ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy |
| Q34183433 | ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter |
| Q38991152 | Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients |
| Q28081844 | Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? |
| Q40668019 | Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia |
| Q36562926 | Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients |
| Q38899401 | Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? |
| Q51064463 | Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations. |
| Q42979936 | Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib |
| Q28478165 | Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia |
| Q41483822 | HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients |
| Q39411920 | Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors |
| Q34348134 | Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. |
Search more.